Answers are grounded in this paper and cite their sources.
Preclinical study demonstrates that 4-aminopyridine restores cerebellar Purkinje cell firing and relieves motor deficits in SCA6 mice, indicating a potential therapeutic strategy for patients.
Spinocerebellar ataxia type 6 (SCA6) is a devastating midlife-onset autosomal dominant motor control disease with no known treatment. Using a hyper-expanded polyglutamine (84Q) knock-in mouse, we found that cerebellar Purkinje cell firing precision was degraded in heterozygous (SCA6(84Q/+)) mice at 19 months when motor deficits are observed. Similar alterations in firing precision and motor control were observed at disease onset at 7 months in homozygous (SCA6(84Q/84Q)) mice, as well as a reduction in firing rate. We further found that chronic administration of the FDA-approved drug 4-aminopyridine (4-AP), which targets potassium channels, alleviated motor coordination deficits and restored cerebellar Purkinje cell firing precision to wildtype (WT) levels in SCA6(84Q/84Q) mice both in acute slices and in vivo. These results provide a novel therapeutic approach for treating ataxic symptoms associated with SCA6.
No takes yet. Share an insight, caveat, or question.
Jayabal et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: